Aphelion Managing Partner Ned Scheetz Discusses Medtech Investor’s Unique Approach, Unusual Name
Jul 30, 2018•32 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Medtech start-ups need more firms like Aphelion Capital, investors willing to wager as little as $200,000 to get a promising idea going. Managing Partner Ned Scheetz discusses the firm’s origins, name, and plans going forward. This is the first of a two-episode package highlighting a unique joint effort between Aphelion and other co-creators of Cardeation Capital.
For the best experience, listen in Metacast app for iOS or Android